Skip to content

Gait and Functional Improvement in Total Knee Arthroplasty With the Use of Verasense for Soft Tissue Balancing

PILOT STUDY: Gait and Functional Improvement in Total Knee Arthroplasty With the Use of Verasense for Soft Tissue Balancing: A Randomized, Double-Blind, Controlled Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02290119
Enrollment
20
Registered
2014-11-13
Start date
2018-04-01
Completion date
2022-10-12
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Primary PCL-retaining Total Knee Arthroplasty, Intraoperative Sensors, Ligament Balancing, Clinical Outcomes

Brief summary

The primary objectives of this study are to understand the effects of soft-tissue balancing on Gait, function and rehabilitation potential after sensor-assisted Total Knee Arthroplasty and correlate Intra-operative subjective feel with OrthoSensor Outputs Secondary objectives are to quantify and observe: * Pain medication use * Swelling * Muscle strength and girth * Gait efficiency * Patient satisfaction * Activity levels, functional return (i.e., back to work, resume normal activities) * Patient perception of a balanced knee

Interventions

DEVICESensor-assisted TKR (Verasense)

Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.

PROCEDUREControl - Without the use of Verasense

Patients in this cohort will undergo manual total knee replacement without the use of Verasense

Sponsors

Orthosensor, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject must be a candidate for a primary PCL retaining total knee arthroplasty * Subject must be diagnosed with one or more of the following conditions: osteoarthritis, avascular necrosis, rheumatoid or other inflammatory arthritis, post-traumatic arthritis * Subject is between the age of 45 - 80 years * Subject is likely to be available for all study visits * Subject is able and willing to sign the informed consent and follow study procedures

Exclusion criteria

* Prior total knee arthroplasty, ligament insufficiencies, prior surgeries such as ACL or PCL reconstructions, posterolateral reconstructions, osteotomies, tibia plateau fractures * Range of Motion less than 90 degrees, flexion contracture of more than 20 degrees

Design outcomes

Primary

MeasureTime frame
Rehabilitation Potential6 Months

Secondary

MeasureTime frameDescription
Knee Society Pain and Functional Scoring (KSS)6 monthThe Knee Society Clinical Rating System is comprised of two distinct sub-scores: one for pain, range of motion (ROM) and joint stability, and one for functional parameters. Sub-scores range from a potential minimum score of 0 to a maximum score of 100 points. Although the specific scores are not distinguished as excellent, good, fair, or poor, a higher value represents a better outcome.
Forgotten Joint Score (FJS)6 monthThe FJS is based on the patients' ability to forget about a joint as a result of the treatment. The FJS assessment is scored on a 0-100 scale. The higher the score, the less the patient is aware of their affected joint when performing daily activities.
3D Gait Analysis velocity6 Month3D gait analysis relates to the range of motion of a joint and the movement velocity. The mean gait speed analysis is considered higher than 1 m/s.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026